Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration and solute removal; low magnesium formulation reduces magnesium accumulation in renal failure patients.
Delflex with Dextrose 2.5% is a peritoneal dialysis solution that provides osmotic ultrafiltration and electrolyte replacement. Dextrose creates an osmotic gradient across the peritoneal membrane, promoting fluid removal. The solution corrects electrolyte imbalances and removes metabolic waste products via diffusion and convection.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day; dextrose concentration and fill volume adjusted based on ultrafiltration needs.
Intraperitoneal administration: 2-3 L per exchange, 4 exchanges per day, with dwell times of 4-6 hours; typical total volume 8-12 L daily.
None Documented
None Documented
Terminal elimination half-life not applicable; drug effects persist as long as solution remains in peritoneal cavity (dwell time 4–8 hours for CAPD).
2 hours (peritoneal dwell time; systemic absorption minimal; continuous ambulatory peritoneal dialysis (CAPD) exchanges every 4-6 hours maintain steady state)
Renal: 99% (as glucose and electrolytes), biliary/fecal: <1%
Renal: 100% (as unchanged drug in urine; no metabolism)
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution